Diasorin has signed an agreement with Beckman Coulter Diagnostics to supply i Liaison XL test for hepatitis A, B and C, as well as HIV testing.
Once the approval from the FDA for marketing in the American territory has been obtained, Beckman Coulter and Diasorin "will offer US laboratories the possibility of accessing the complete menu of tests for hepatitis and HIV," reads a statement from the Saluggia group. on Liaison XL Las analyzers, connected to automated analyzers from Beckman Coulter, Power Express and Power Processor”.
Diasorin will keep the right to commercialize the same tests on Liaison XL stand-alone analyzers, “pursuing the strategy of penetrating hospital laboratories with lower test volumes required, where complete laboratory automation is not considered fundamental”. Diasorin estimates that the US market for these tests, excluding blood banks, represents a potential opportunity of $500 million.
At the moment, the share of the group led by Carlo Rosa is not reacting particularly to the announcement: around 10,10, in fact, Diasorin rose by 1,23%, to 57,55 euros, after having reached a maximum of 57,6 ,XNUMX euros.
